Nucleome Therapeutics Raises £37.5M in Series A Financing

▤ Summary

Nucleome Therapeutics, an Oxford, UK-based biotechnology company decoding the dark matter of the human genome, raised £37.5M in Series A funding. The company intends to use the funds to advance its autoimmune disease programs, accelerate expansion of its dark genome atlas and further develop its platform. Led by CEO Dr Danuta Jeziorska, Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat disease. The dark genome holds more than 90% of disease-linked genetic variants whose value remains untapped, representing a significant opportunity for drug discovery and development. The company has the ability to link these variants to gene function and precisely map disease pathways.

▦ Linked Companies